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Canonical Wnt/b-catenin signaling mediates
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Transforming growth factor-b1 (TGF-b1) upregulation occurs
in virtually all chronic kidney diseases and is associated with
podocyte injury and proteinuria; however, the mechanisms
contributing to this in vivo are ambiguous. In vitro, incubation
of podocytes with TGF-b1 induced Wnt1 expression, b-catenin
activation, and stimulated the expression of Wnt/b-catenin
downstream target genes. Ectopic expression of Wnt1 or
b-catenin mimicked TGF-b1, induced Snail1, and suppressed
nephrin expression. The Wnt antagonist, Dickkopf-1, blocked
TGF-b1-induced b-catenin activation, Snail1 induction,
and nephrin suppression. In vivo, ectopic expression of
TGF-b1 induced Wnt1 expression, activated b-catenin, and
upregulated Wnt target genes such as Snail1, MMP-7, MMP-9,
desmin, Fsp1, and PAI-1 in mouse glomeruli, leading to
podocyte injury and albuminuria. Consistently, concomitant
expression of Dickkopf-1 gene abolished b-catenin activation,
inhibited TGF-b1-triggered Wnt target gene expression,
and mitigated albuminuria. Thus, canonical Wnt/b-catenin
signaling mediates TGF-b1-driven podocyte injury and
proteinuria. These studies suggest that Wnt/b-catenin
signaling may be exploited as a therapeutic target for
the treatment of proteinuric kidney diseases.
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Podocyte injury is one of the major culprits resulting in
an impaired glomerular filtration, which is manifested by
proteinuria in the clinical setting.1 Characterized as termi-
nally differentiated glomerular visceral epithelial cells with
highly sophisticated foot processes, podocytes possess little
proliferative capacity in adult kidneys and are susceptible
to various metabolic, hemodynamic, immune, and toxic
injuries.2,3 Transforming growth factor-b1 (TGF-b1), a
potent fibrogenic cytokine that is upregulated in virtually
all kinds of chronic kidney diseases,4,5 is a well-characterized
pathogenic factor that regulates podocyte structure and
function in a hostile way. In vitro, TGF-b1 has been shown
to induce podocytes to undergo epithelial–mesenchymal
transition (EMT),6 and at a high concentration it triggers
podocyte apoptosis.7 Aberrant regulation of TGF-b1 expres-
sion is clearly associated with podocyte dysfunction and
proteinuria in patients with various chronic kidney disorders.
Transgenic mice overexpressing TGF-b1 under albumin
promoter spontaneously develop proteinuria and progressive
kidney disease.8,9 These studies have clearly established an
intimate linkage of hyperactive TGF-b1 to the pathogenesis
of podocyte injury and proteinuria. However, exactly how
TGF-b1 induces podocyte injury in vivo remains poorly
understood.
Wnt/b-catenin signaling is an evolutionarily conserved,
outside-in signal pathway that has a fundamental role in
controlling many biological processes such as embryonic
development and tissue homeostasis.10,11 At the cellular level,
this signaling regulates cell morphology, proliferation,
motility, and cell fate. At least two Wnt ligands, Wnt4 and
Wnt9b, are clearly involved in the epithelial differentiation
of metanephric mesenchymal progenitors during nephron
formation,12,13 whereas they are considered to be silent in adult
kidney. Inappropriate expression of Wnts and reactivation of
b-catenin are common findings in a wide variety of kidney
diseases in animal models and in humans, including obstructive
nephropathy, adriamycin nephropathy, ischemia/reperfusion-
induced acute kidney injury, polycystic kidney diseases, chronic
allograft nephropathy, and diabetic nephropathy.14–17
Depending on different receptors and cellular content,
Wnt proteins can activate and transduce their intracellular
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signaling through both canonical (b-catenin-dependent) and
non-canonical (b-catenin-independent) pathways.10,11 Earlier
studies have shown that the canonical Wnt/b-catenin signal-
ing is decisively implicated in the pathogenesis of podocyte
dysfunction and proteinuria, as genetic ablation of b-catenin
in a podocyte-specific manner protects mice against develop-
ment of proteinuria after adriamycin injury.15,18 Pharmacological
activation of b-catenin by lithium chloride causes proteinuria
in mice,15 whereas inhibition of Wnt/b-catenin by pari-
calcitol mitigates an established proteinuria in adriamycin
nephropathy.19 These findings led us to hypothesize that
canonical Wnt/b-catenin signaling might have a role in
mediating TGF-b1-driven podocyte injury and proteinuria.
In this study, we demonstrate that hyperactive TGF-b1
alone is sufficient to induce podocyte injury and proteinuria
in healthy mice, which is accompanied by Wnt1 induction,
b-catenin activation, and induction of numerous Wnt target
genes in the glomeruli. Consistently, inhibition of Wnt signal-
ing by its antagonist ameliorates TGF-b1-triggered podocyte
injury in vivo, suggesting a crucial role for the canonical Wnt/
b-catenin signaling in mediating this process. Therefore, target-
ing this signaling could offer renal protection against the
development and progression of proteinuric kidney diseases.
RESULTS
Induction of Wnt expression by TGF-b1 in podocytes
We first performed a systematic analysis of the mRNA
expression of all Wnt genes in cultured mouse podocytes
after incubation with TGF-b1 by reverse transcription-PCR
(RT-PCR) approach. As shown in Figure 1a, a comprehensive
survey of all 19 Wnts revealed a marked induction of Wnt1
mRNA expression in podocytes after TGF-b1 treatment.
Several other Wnts, including Wnt2, Wnt9a, Wnt10b, and
Wnt11, was also induced at different time points, whereas a
slight inhibition of Wnt5b and Wnt16 was evident,
particularly at later time points. Notably, the expression of
Wnt3a, Wnt4, and Wnt9b was undetectable in cultured
podocytes throughout the experiments (data not shown).
Among all Wnts examined, the induction of Wnt1 mRNA
by TGF-b1 was most predominant. Quantitative real-time
RT-PCR results revealed that Wnt1 mRNA expression was
induced byB14-fold at 8 h after TGF-b1 treatment in mouse
podocytes (Figure 1b). The induction of Wnt1 mRNA
expression also occurred in a dose-dependent manner, and
TGF-b1 induced its mRNA level at the concentration as low
as 0.5 ng/ml, which reached the peak at 2 ng/ml (Figure 1c).
Notably, induction of Wnt1 was dependent on TGF-b
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Figure 1 | Expression of Wnt genes is induced by transforming growth factor-b1 (TGF-b1) in podocytes. (a) Reverse transcription-PCR
(RT-PCR) demonstrates an altered expression of various Wnts mRNA in cultured mouse podocytes after treatment with TGF-b1 at 2 ng/ml
for various periods of time as indicated. (b, c) Quantitative real-time RT-PCR reveals that TGF-b1 induced Wnt1 mRNA expression in a time-
and dose-dependent manner. Wnt1 mRNA levels were assessed by real-time RT-PCR in mouse podocytes after treatment with a fixed
amount of TGF-b1 (2 ng/ml) for various periods of time as indicated (b) or with various concentrations of TGF-b1 for 24 h (c). *Po0.05;
**Po0.01 versus controls (n¼ 3). (d) Induction of Wnt1 by TGF-b1 is dependent on TGF-b receptor signaling. Mouse podocytes were
pretreated with TGF-b type I receptor inhibitor SB431542 at 10 mmol/l for 1 h, and then treated with TGF-b1 at 2 ng/ml for 8 h. Wnt1 mRNA
was assessed by real-time RT-PCR. *Po0.05 (n¼ 3).
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receptor signaling, as SB431542, an inhibitor of TGF-b type I
receptor, completely abolished Wnt1 induction by TGF-b1 in
podocytes (Figure 1d).
TGF-b1 activates b-catenin and induces its target gene
expression
To examine the biological consequence of Wnt induction in
podocytes, we next investigated the activation of b-catenin,
the principal downstream mediator of canonical Wnt
signaling, in podocytes after TGF-b1 treatment. As shown
in Figure 2a, active, dephosphorylated form of b-catenin
protein was induced in cultured mouse podocytes at 24 h
after incubation with TGF-b1, which sustained to 48 h.
This activation of b-catenin significantly lagged behind
the Wnt1 mRNA induction by TGF-b1. The induction
of active b-catenin protein was also dose dependent, and
TGF-b1 induced active b-catenin at a concentration as low
as 0.5 ng/ml, which reached the peak at 2 ng/ml (Figure 2b).
We further examined b-catenin activation and its subcellular
distribution in podocytes after incubation with TGF-b1 for
24 h. As illustrated in Figure 2c, b-catenin predominantly
displayed a plasma membrane-associated staining pattern in
the resting, control podocytes (Figure 2c, arrowhead). However,
upon stimulation by TGF-b1, b-catenin underwent nuclear
translocation, with disappearance of the plasma membrane-
associated staining and concomitant emergence of nuclear
b-catenin (Figure 2c, arrowheads). This nuclear translocation
of b-catenin, together with the western blot results (Figure 2a
and b), clearly indicates the activation of canonical Wnt/
b-catenin signaling in podocytes after TGF-b1 treatment.
We examined the expression of several putative target
genes of Wnt/b-catenin after TGF-b1 stimulation in podo-
cytes. As shown in Figure 2d–g, MMP-9, MMP-7, PAI-1,
and LEF-1 were induced by TGF-b1 in podocytes, as
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Figure 2 | Transforming growth factor-b1 (TGF-b1) activates b-catenin and induces its target gene expression in podocytes.
(a, b) Western blot analyses demonstrate that TGF-b1 induced active b-catenin protein expression in a time- and dose-dependent
manner. Podocytes were treated with a fixed amount of TGF-b1 (2 ng/ml) for various periods of time as indicated (a) or with various
concentrations of TGF-b1 for 48 h (b). Total cell lysates were immunoblotted with specific antibodies against active b-catenin and a-tubulin,
respectively. (c) Immunofluorescence staining demonstrates the activation of b-catenin and nuclear translocation in mouse podocytes after
treatment with TGF-b1 (2 ng/ml) for 24 h. Arrowheads indicate b-catenin staining. (d–g) TGF-b1 induces the expression of Wnt/b-catenin
target genes in podocytes. Mouse podocytes were incubated with TGF-b1 (2 ng/ml) for 24 h. The expression of Wnt/b-catenin target
genes MMP-9 (d), MMP-7 (e), PAI-1 (f), and LEF-1 (g) was assessed by real-time reverse transcription-PCR (RT-PCR). **Po0.01 (n¼ 3).
(h) TGF-b1/Wnt1/b-catenin cascade is sufficient for triggering nephrin suppression and Snail1 induction in podocytes. Mouse podocytes
were incubated with TGF-b1 at 2 ng/ml for 48 h, or transiently transfected with expression vector pHA-Wnt1, pDel-b-cat, or pcDNA,
respectively. Representative RT-PCR results demonstrated the mRNA expression of nephrin and Snail1. (i, j) Treatment of mouse podocytes
with Dickkopf-1 (DKK1) preserves nephrin mRNA expression repressed by TGF-b1. Podocytes were pretreated with recombinant protein
DKK1 at 40 or 200 ng/ml for 1 h, followed by the treatment with TGF-b1 at 2 ng/ml. Representative RT-PCR results (i) and quantitative data (j)
demonstrate the mRNA expression of nephrin. *Po0.05 versus group treated with TGF-b1 alone (n¼ 3). DAPI, 40,6-diamidino-2-
phenylindole.
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demonstrated by quantitative real-time RT-PCR analyses. We
also assessed the expression of nephrin and Snail1, two genes
that are directly relevant to podocyte dysfunction. As shown
in Figure 2h, TGF-b1 induced Snail1 and suppressed nephrin
expression in podocytes, as previously reported.6 Transient
transfection with either Flag-tagged N-terminal truncated,
stabilized b-catenin expression vector (pDel-b-cat) or HA-
tagged Wnt1 expression vector (pHA-Wnt1) mimicked the
action of TGF-b1. Furthermore, preincubation with recom-
binant Dickkopf-1 (DKK1), a secreted Wnt antagonist that
specifically blocks the canonical pathway of Wnt signaling,20
was able to preserve, at least partially, nephrin expression in a
dose-dependent manner (Figure 2i and j). These results
suggest an important role for Wnt/b-catenin in mediating
the pathogenic action of TGF-b1 in podocytes.
Ectopic expression of TGF-b1 targets glomerular podocytes
in vivo
To investigate the potential role of TGF-b1/Wnt1/b-catenin
signaling in podocyte injury in vivo, we sought to express
bioactive, exogenous TGF-b1 by use of a hydrodynamic-
based gene delivery approach.21–23 As shown in Figure 3a,
several mammalian expression plasmid vectors were con-
structed, which contained the coding region of mouse
wild-type TGF-b1 (pWT-TGF-b1), C-terminus mature
TGF-b1 (pCT-TGF-b1), and constitutively active TGF-b1
(pCA-TGF-b1), respectively. The pCA-TGF-b1 vector
contained two cysteine to serine mutations at the positions
223 and 225 (C223S/C225S), which produces bioactive
TGF-b1 that does not require acid activation,24 rendering it
constitutively active. To test the bioactivity of these TGF-b1
expression vectors, we examined their ability to induce the
expression of PAI-1, a sensitive TGF-b1 target gene.25 As
shown in Figure 3b, little PAI-1 induction was observed in
podocytes after transient transfection with either pWT-TGF-b1
or pCT-TGF-b1, compared with empty vector pcDNA3.
However, transfection with pCA-TGF-b1 significantly induced
PAI-1 expression, corroborating the bioactivity of this mutant,
constitutively active TGF-b1 (Figure 3b). Furthermore, tran-
sient transfection of mouse podocytes with pCA-TGF-b1
induced b-catenin activation and Snail1 expression, which
was largely abrogated by coexpression of DKK1 gene (Figure
3c and d). It is noteworthy that transfection DKK1 gene in
podocytes did not affect the expression of TGF-b1 transgene
(Supplementary Figure S1 online).
We next administrated the pCA-TGF-b1 expression plasmid
into mice by a single intravenous injection. As shown in Figure 4a
and b, single administration of pCA-TGF-b1 plasmid markedly
increased TGF-b1 protein levels in the blood circulation and in
the glomeruli, as detected by a specific enzyme-linked immuno-
sorbent assay (ELISA) at 18h after plasmid injection. Figure 4c
shows that Smad3 phosphorylation, a surrogate marker for
TGF-b receptor activation, was observed in the glomerular
lysates of the kidneys at 1 or 2 days after injection. Double
immunofluorescence staining for both phosphorylated Smad3
(red) and nephrin (green) revealed that podocytes in the
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Figure 3 | Ectopic expression of transforming growth factor-b1 (TGF-b1) in podocytes activates b-catenin in a Wnt-dependent
manner. (a) Diagram depicts the construction of wild-type TGF-b1 (pWT-TGF-b1), C-terminus mature TGF-b1 (pCT-TGF-b1), and
constitutively active TGF-b1 (pCA-TGF-b1) expression vectors. (b) Expression vector pCA-TGF-b1 markedly induces PAI-1 gene expression
in podocytes. Mouse podocytes were transiently transfected with expression vector pWT-TGF-b1, pCT-TGF-b1, pCA-TGF-b1 and pcDNA3
for 48 h, respectively. Total cell lysates were immunoblotted with specific antibodies against PAI-1 and actin, respectively. (c) Ectopic
expression of TGF-b1 activates b-catenin in podocytes, which is blocked by Wnt antagonist Dickkopf-1 (DKK1). Podocytes were transfected
with constitutively active TGF-b1 expression vector (pCA-TGF-b1), DKK1 expression vector (pFlag-DKK1), or empty vector pcDNA3,
as indicated, for 48 h. Total cell lysates were immunoblotted with specific antibodies against active b-catenin and a-tubulin, respectively.
(d) DKK1 reduces TGF-b1-mediated Snail1 induction. Mouse podocytes were transfected with various plasmids as indicated for 48 h.
Snail1 mRNA expression was assessed by real-time reverse transcription-PCR. *Po0.05; **Po0.01 (n¼ 3).
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glomeruli were preferentially responsive to TGF-b1, with a
positive staining for phosphorylated Smad3 after TGF-b1
gene delivery (Figure 4d, arrowheads), although Samd3
activation in tubular cells was also evident. Weak staining
for phosphorylated Smad3 was detectable in the mesangial
area in normal control kidneys, but it did not significantly
increase after pCA-TGF-b1 injection.
TGF-b1 activates Wnt/b-catenin signaling in podocytes in vivo
We examined the effects of TGF-b1 on Wnt/b-catenin signal-
ing in podocyte in vivo. Quantitative real-time RT-PCR results
revealed an increased expression of Wnt1 gene in the glomeruli,
which was detected at day 1 and sustained at day 2 after TGF-b1
plasmid injection (Figure 5a). Immunostaining also demon-
strated an increased Wnt1 protein in mouse glomeruli after
pCA-TGF-b1 injection (Figure 5b, arrowheads). Subcellular
fractionation of the isolated glomeruli, followed by western
blot analyses, indicated that b-catenin in both cytoplasmic
and nuclear compartments was markedly induced after TGF-b1
gene delivery in vivo (Figure 5c). Compared with pcDNA3
controls, ectopic expression of TGF-b1 clearly promoted
b-catenin to undergo nuclear translocation (Figure 5c), sugges-
ting the activation of canonical Wnt signaling.
We further studied the expression of several putative Wnt/
b-catenin target genes in the glomeruli after TGF-b1 gene
delivery. As shown in Figure 5d–i, numerous well-character-
ized Wnt/b-catenin target genes, including Snail1, MMP-9,
MMP-7, desmin, fibroblast-specific protein (Fsp1)/S100A4,
and PAI-1, were upregulated in mouse glomeruli after ectopic
expression of exogenous TGF-b1.
Ectopic expression of TGF-b1 induces podocyte injury and
proteinuria
We next investigated the functional consequence of Wnt/
b-catenin activation in podocytes by TGF-b1 in vivo. Analysis
of urine samples revealed that urinary albumin levels were
substantially increased in mice that received TGF-b1 plasmid
injection, compared with pcDNA3 controls (Figure 6a). SDS-
polyacrylamide gel electrophoresis analysis demonstrated that
albumin was the major constituent of urine proteins in these
mice (Figure 6b), suggesting defective glomerular filtra-
tion. Consistently, exogenous TGF-b1 induced an altered
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nephrin distribution, from a linear staining along glomerular
basement membrane to granular pattern, as illustrated by
immunofluorescence staining, although it did not signifi-
cantly affect nephrin abundance (Figure 6c).
The expression of Wilms tumor 1 (WT1), an important
transcription factor that is exclusively expressed in podo-
cytes in adult kidney, was significantly suppressed after
TGF-b1 plasmid injection (Figure 6d). The inhibition
of WT1 expression by TGF-b1 was confirmed in vitro
(Figure 6e). However, coincubation with DKK1 and
TGF-b1 did not restore WT1 expression (Figure 6e), sug-
gesting that it is independent of Wnt signaling. A diagram
showing the TGF-b1 signaling leading to podocyte injury is
presented in Figure 6f.
Ectopic expression of DKK1 gene blocks Wnt/b-catenin
signaling and reduces proteinuria
To validate a role of Wnt/b-catenin signaling in mediating
TGF-b1-induced podocyte injury and proteinuria, we sought
to block Wnt signaling in vivo by its natural antagonist
DKK1. To this end, mice were injected concurrently with
TGF-b1 expression vector (pCA-TGF-b1) in the presence or
absence of DKK1 expression vector (pFlag-DKK1). Renal
expression of exogenous DKK1 by this approach was
reported previously.14 As shown in Figure 7a, ectopic
expression of constitutively active TGF-b1 induced both
active and total b-catenin expression in the glomeruli, as
demonstrated by western blot analyses of glomerular lysates.
However, concomitant expression of DKK1 gene abolished
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b-catenin induction and activation. Immunohistochemical
staining produced similar results. As shown in Figure 7b, renal
b-catenin protein was increased in glomerular podocytes
and tubular cells after ectopic expression of TGF-b1 (Figure
7b, arrowheads). The positive b-catenin staining localized in
the cytoplasmic and nuclear compartments was significantly
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diminished when DKK1 gene was concurrently admini-
strated. Interestingly, delivery of DKK1 gene significantly
mitigated albuminuria induced by TGF-b1 (Figure 7c),
indicating an important role for Wnt/b-catenin signaling in
mediating TGF-b1-induced podocyte injury and proteinuria.
We next examined the expression of Wnt/b-catenin
downstream target genes in the glomeruli of these mice. As
shown in Figure 8a–e, administration of DKK1 gene resulted
in significant inhibition of the Wnt/b-catenin target genes.
Quantitative RT-PCR revealed that DKK1 significantly
inhibited the mRNA expression of Snail1, MMP-9, MMP-7,
LEF-1, and PAI-1 genes, which were induced in mouse
glomeruli after TGF-b1 expression (Figure 8).
DISCUSSION
The results presented here clearly illustrate a critical role for
Wnt/b-catenin signaling in meditating the pathogenesis of
podocyte injury and proteinuria in vivo after ectopic
expression of TGF-b1. We demonstrate that Wnt1 is
upregulated and b-catenin is activated in the glomeruli after
ectopic expression of TGF-b1 through a hydrodynamic-based
gene delivery approach, which leads to the overexpression of
several key Wnt target genes including Snail1, resulting in
podocyte injury and onset of proteinuria. Moreover, Wnt
antagonist DKK1 is effective in blocking TGF-b1-mediated
b-catenin activation in vivo and in vitro, leading to signi-
ficant inhibition of Wnt target genes and mitigation of
albuminuria in mice. These studies establish a simple mouse
model in which ectopic expression of TGF-b1, per se, is
sufficient to cause podocyte injury in vivo and result in
proteinuric kidney disease. Our data also underscore that
targeting Wnt/b-catenin could be a promising novel thera-
peutic strategy for the treatment of a variety of proteinuric
kidney disease in humans.
TGF-b1, as a fibrogenic factor, is upregulated in the injured
kidneys in experimental animal models and in humans of
virtually every type of chronic kidney diseases.4,5 Although
hyperactive TGF-b signaling is considered to be a major
profibrotic stimulus in mesangial injury and expansion, little is
known about its pathological action in podocytes in vivo.
Earlier studies on transgenic mice overexpressing TGF-b1
under albumin promoter (Alb/TGF-b1 mice) have pointed
toward a causative role of TGF-b1 in the pathogenesis of
nephropathies, as these mice spontaneously develop protein-
uria, progressive glomerulosclerosis, and interstitial fibrosis,
with advanced kidney failure leading toB25% animal death at
5–12 weeks of age.8,9 However, perhaps owing to tremendous
heterogeneity in renal pathology and the difficulty to maintain
the colony, these mice have not been widely used as an animal
model of chronic kidney diseases. In this study, by a single
injection of naked plasmid vector encoding constitutively active
TGF-b1, we have established a simple, quick, reproducible, and
accessible mouse model of podocyte injury and proteinuria
(Figure 6). As TGF-b1 is the sole culprit of kidney injury in this
model, these mice could also serve as an in vivo model to
dissect the cellular and molecular mechanism of TGF-b1 action
in the kidneys. Interestingly, of the three major cell types in
the glomeruli, podocytes seem to be the most susceptible
cells that are readily responsive to TGF-b1 stimulation in vivo,
as illustrated by Smad3 phosphorylation (Figure 4). Such an
activation of TGF-b1 leads to induction of numerous Wnt
genes, particularly and predominantly Wnt1 (Figures 1 and 5),
which results in the stabilization and accumulation of
b-catenin, as well as its nuclear translocation. In addition,
TGF-b1 and Wnts may work in concert to regulate gene
expression, as previous studies suggest that b-catenin can
interact and cross-talk with Smads.26 In short, TGF-b1 is
categorically linked to the activation of Wnt/b-catenin, a
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developmental signaling that is recently implicated in podocyte
dysfunction and proteinuria.15
How activation of Wnt/b-catenin signaling causes podo-
cyte injury remains elusive, but it could be related to its
ability to regulate podocyte dedifferentiation and EMT, a cell
phenotypic alteration process taking place in embryonic
development, cancer metastasis, and tissue fibrosis.27–29
Previous studies demonstrate that podocytes are able to
undergo EMT in vitro after TGF-b1 stimulation, and this
process could be a potential pathway leading to podocyte
dysfunction and proteinuria under pathological conditions.6
In agreement with this notion, EMT has been proposed as
a potential explanation for podocyte dysfunction, detach-
ment, and depletion in human diabetic nephropathy.30 It is
interesting to point out that Snail1, a key transcription
factor controlling EMT,31–33 is a downstream target gene of
Wnt/b-catenin signaling.34 Snail1, in turn, could directly
suppress nephrin expression in podocytes and induces the
expression of other mesenchymal markers.15,35 Indeed, either
incubation with TGF-b1 or overexpression of Wnt1 or
stabilized b-catenin is sufficient to induce Snail1 expression
and suppress nephrin expression in podocytes (Figure 2).
However, ectopic expression of TGF-b1 in vivo does not
suppress nephrin expression (Figures 4 and 5), although
TGF-b1/Wnt1/b-catenin cascade induces Snail1 both in vitro
and in vivo. The reason behind this discrepancy between
in vitro and in vivo nephrin regulation by TGF-b1 is
unknown. It is possible that TGF-b1 in vivo, a much more
complex setting, is able to cross-talk and interact with other
signal routes, resulting in divergent regulation of nephrin
expression. This issue clearly needs more studies.
It should be noted that TGF-b1 not only induces Wnt1 but
also represses WT1 via a mechanism independent of Wnt1. As
WT1 is a known negative regulator of b-catenin signaling,36,37
and loss of WT1 would lead to derepression of b-catenin
activity, this suggests that TGF-b1 may activate b-catenin
through both Wnt1-dependent and WT1-dependent pathways
(Figure 6f), which could lead to an exaggerated expression
of its downstream target genes. Besides Snail1, numerous
b-catenin target genes are identified to be activated in the
glomeruli upon TGF-b1 expression, such as MMP-9, MMP-7,
LEF-1, Fsp1, and PAI-1. Among these genes, induction of
LEF-1, a DNA-binding transcription factor that interacts with
b-catenin by forming a trans-activation protein complex,38
clearly favors a positive feedback loop that re-enforces Wnt
signaling. MMPs are a family of extracellular proteases that are
responsible for the degradation of the extracellular matrix and
other substrates during tissue remodeling.39 Although the
exact action of MMPs in podocyte injury is unclear,
MMP-mediated extracellular domain shedding of slit
diaphragm-associated proteins could have a role.40 PAI-1, a
well-characterized fibrogenic factor, is another direct down-
stream target of Wnt/b-catenin signaling,25 and its induction
may also contribute to the development of nephropathy in
mice after TGF-b1 expression.41 It is conceivable that each of
these target genes activated by Wnt/b-catenin could promote
podocyte injury and proteinuria in their own ways. However,
it is interesting to note that many of these genes, including
Snail1, MMPs, Fsp1, and PAI-1, share the same property by
promoting cell migration.41–43 An increased podocyte migra-
tion could render them from stationary to motile state, which
could reduce their adhesions to glomerular basement
membrane and promote detachment. This view is in line
with previous observation that EMT leads to an increased
podocyte detachment and depletion in diabetic nephropathy.30
Our present study also indicates that targeting Wnt/b-
catenin signaling might be an effective strategy to mitigate
podocyte injury and proteinuria. DKK1, a secreted Wnt
antagonist, specifically binds to the Wnt coreceptors LRP-5/6,
leading to blockade of the canonical Wnt signaling.20,44
Indeed, DKK1 gene therapy blocks b-catenin activation,
suppresses Wnt/b-catenin target gene expression, and miti-
gates albuminuria. Notably, perhaps because DKK1 merely
blocks Wnt1-dependent, but not WT1-dependent, b-catenin
signaling (Figure 6f), it displays a partial amelioration of
proteinuria after TGF-b1 injection (Figure 7c). This suggests
that direct inhibition of b-catenin could be a better strategy
for renal protection, although not tested yet. As multiple
strategies to target Wnt/b-catenin are currently available,
more studies are warranted in the future to evaluate their
therapeutic efficacy in the preclinical setting.
MATERIALS AND METHODS
Cell culture and treatment
The conditionally immortalized mouse podocyte cell line was kindly
provided by Dr Peter Mundel and maintained as described previously.6
To propagate podocytes, cells were cultured at 33 1C in RPMI-1640
medium supplemented with 10% fetal bovine serum and recombinant
interferon-g (Invitrogen, CarIsbad, CA). To induce differentiation,
podocytes were grown under nonpermissive conditions at 37 1C in the
absence of interferon-g and in the presence of retinoic acid (106mol/l)
and 1,25-dihydroxyvitamin D (107mol/l).45 Podocytes were treated
with recombinant TGF-b1 (R&D Systems, Minneapolis, MN) at the
concentration of 2 ng/ml, unless otherwise indicated. Recombinant
mouse DKK1 (R&D Systems) was used for pretreatment at 40 or
200ng/ml for 1 h, followed by incubation with TGF-b1 for 24h.
For inhibiting TGF-b receptor signaling, podocytes were pretreated
with SB431542 (Tocris Bioscience, Ellisville, MO) at 10mmol/l for 1 h,
followed by incubation with TGF-b1. For some studies, podocytes
were transiently transfected with either HA-tagged Wnt1 expression
vector (pHA-Wnt1; Upstate Biotechnology, Lake Placid, NY),
Flag-tagged N-terminal truncated, stabilized b-catenin expression
vector (pDel-b-cat), constitutively active TGF-b1 expression vector
(pCA-TGF-b1; see below), or Flagged-tagged DKK1 expression vector
(pFlag-DKK1; provided by Dr Xi He, Harvard Medical School, Boston,
MA) by using Lipofectamine 2000 reagent (Invitrogen), as described
previously.15
Construction of pCA-TGF-b1 vector
The expression plasmid vectors containing mouse wild-type TGF-b1
(pWT-TGF-b1), C-terminus mature TGF-b1 (pCT-TGF-b1), and
constitutively active TGF-b1 (pCA-TGF-b1) were constructed by
using standard molecular cloning techniques. The pCA-TGF-b1
vector contained two cysteine to serine mutations at the positions
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223 and 225 (C223S/C225S). This expression vector was constructed
by using the QuikChange II XL site-directed mutagenesis kit, and it
produces bioactive TGF-b1 that does not require acid activation,
as reported previously.24 The correct sequences of different expres-
sion vectors were confirmed by sequencing at the DNA Sequencing
Core Facility of the University of Pittsburgh.
Animal models
Male BALB/c mice that weighed B20–22 g were purchased from
Harlan Sprague Dawley (Indianapolis, IN). For delivery of mouse
TGF-b1 gene, constitutively active TGF-b1 expression plasmid
(pCA-TGF-b1) was injected intravenously at 0.3mg/kg body weight
by using a hydrodynamics-based in vivo gene transfer approach, as
described previously.21,22 For delivery of human DKK1 gene, naked
DKK1 expression plasmid (pFlag-DKK1) was injected intravenously
at 2mg/kg body weight by using the same approach. Control mice
were administered an injection of empty vector pcDNA3 plasmid in
an identical manner. Mice were killed at day 1 and day 2 after
injection, and kidney tissues were collected for various analyses.
Animal protocols were approved by the Institutional Animal Care
and Use Committee at the University of Pittsburgh.
Isolation of glomeruli
Glomeruli were isolated by differential sieving technique according
to the method described elsewhere.46 Briefly, the kidneys were
excised and pressed with a spatula through a stainless steel screen of
#100 mesh and rinsed with 1% albumin in cold phosphate-buffered
saline (PBS-A) through successive screens of #200 mesh and #282
mesh, respectively. The glomeruli were collected on the #282-mesh
screen and suspended in PBS-A. After centrifugation at 200 g for
10min, glomeruli were collected for subsequent analyses.
Urinary albumin and creatinine assay
Urinary albumin level was measured by using a mouse Albumin
ELISA Quantification kit, according to the manufacturer’s protocol
(Bethyl Laboratories, Montgomery, TX). Urine creatinine was
determined by a routine procedure as described previously.47
RT-PCR and real-time PCR
Total RNA was extracted using the TRIzol RNA isolation system
(Invitrogen). The first strand of complementary DNA was
synthesized using 2 mg of RNA in 20ml of reaction buffer by reverse
transcription using AMV-RT (Promega, Madison, WI) and random
primers at 42 1C for 30min. PCR was carried out using a standard
PCR protocol with 1 ml aliquot of complementary DNA, HotStarTaq
polymerase (Qiagen, Valencia, CA), and specific primer pairs. The
sequences of the primer pairs were given in Supplementary Table S1
online, whereas the primer pairs of 19 Wnt genes were described
previously.14 For quantitative determination of mRNA levels, a
real-time RT-PCR was performed on an ABI PRISM 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA), as
described previously.48 The PCR reaction mixture in a 25 ml volume
contained 12.5 ml of 2 SYBR Green PCR Master Mix (Applied
Biosystems), 10 ml of diluted reverse transcription product (1:10),
and 0.5mmol/l sense and antisense primer sets. PCR reaction was
run by using standard conditions.48 After sequential incubations at
50 1C for 2min and 95 1C for 10min, the amplification protocol
consisted of 40 cycles of denaturation at 95 1C for 15 s, and
annealing and extension at 60 1C for 60 s. The mRNA levels of
various genes were calculated after normalizing with b-actin.
Western blot analysis
Cultured mouse podocytes were lysed in SDS sample buffer. The
isolated glomeruli were pooled and lysed with radioimmunoprecipita-
tion assay buffer containing 1% NP-40, 0.1% SDS, 100mg/ml
phenylmethylsulfonyl fluoride, 1% protease inhibitor cocktail, and
1% phosphatase I and II inhibitor cocktail (Sigma, St Louis, MO) in
PBS on ice. The supernatants were collected after centrifugation at
13,000 g at 4 1C for 20min. Protein expression was analyzed by western
blot analysis as described previously.6 The primary antibodies used
were as follows: anti-b-catenin (no. 6101541; BD Transduction,
San Jose, CA), anti-dephosphorylated, active b-catenin (no. 05-665;
Millipore, Billerica, MA), anti-phospho-Smad3 (Ser423/425; no. 9514;
Cell Signaling, Boston, MA), anti-Smad1/2/3 (sc-7960; Santa Cruz
Biotechnology, Santa Cruz, CA), anti-PAI-1 (sc-5297; Santa Cruz
Biotechnology), anti-WT1 (ab15249; Abcam, Cambridge, MA) anti-
Histone H3 (ab1791; Abcam), anti-actin (sc-1616; Santa Cruz
Biotechnology), anti-glyceraldehyde 3-phosphate dehydrogenase
(no. 4300; Ambion, Austin, TX), and anti-a-tubulin (T9026; Sigma).
Determination of TGF-b1 levels by ELISA
Plasma and glomerular TGF-b1 levels were determined by using a
commercial Quantikine TGF-b1 ELISA kit in accordance with the
protocol specified by the manufacturer (R&D Systems).23 Briefly,
at 18 h after plasmid injection, mouse plasma was collected and
glomeruli were isolated by differential sieving technique. Glomeruli
were homogenized in the buffer containing 20mmol/l Tris-HCl, pH
7.5, 2mol/l NaCl, 0.1% Tween-80, 1mmol/l EDTA, and 1mmol/l
PMSF, as described previously.22 After centrifugation at 19,000 g for
20min at 4 1C, the supernatant was recovered for determination of
TGF-b1 by ELISA. Plasma and glomerular TGF-b1 levels were
expressed as ng/ml and pg/mg protein, respectively.
Nuclear and cytoplasmic fractionation
For preparation of nuclear protein, isolated mouse glomeruli were
collected and washed twice with cold PBS. Nuclear protein was
prepared using NE-PER Nuclear and Cytoplasmic Extraction
Reagents, according to the protocols specified by the manufacturer
(Thermo Scientific, Rockford, IL), as described previously.49
Immunofluorescent and Immunohistochemical staining
Kidney cryosections at 4-mm thickness were fixed for 15min in 4%
paraformaldehyde, followed by permeabilization with 0.2%. Triton X-
100 in PBS for 10min at room temperature. After blocking with 10%
donkey serum for 60min, slides were immunostained with primary
antibodies against nephrin (Fitzgerald Industries International,
Concord, MA), Wnt1 (ab15251; Abcam), or phosphorylated Smad3
(Ser423/425) (cat. no. 9514, Cell Signaling). To visualize the primary
antibodies, slides were stained with Cy2- or Cy3-conjugated secondary
antibodies (Sigma). The slides were viewed under Olympus FluoView
500 confocal microscope (Olympus, Center Valley, PA). Immuno-
fluorecence staining of cultured podocytes and immunohistochemical
staining of kidney sections was performed by using an established
protocol.47 Cell culture coverslips and paraffin-embedded sections
were stained with polyclonal rabbit anti-b-catenin antibody (ab-15180;
Abcam, Cambridge, MA). Slides were viewed with a Nikon Eclipse
E600 microscope equipped with a digital camera (Melville, NY).
Statistical analysis
All data examined were expressed as mean±s.e.m. Statistical
analysis was performed using SigmaStat software (Jandel Scientific
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Software, San Rafael, CA). Comparison between groups was made
using one-way analysis of variance, followed by the Student–
Newman–Keuls test. A P-value of o0.05 was considered significant.
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